Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Why Shilpa’s bet on Alveolus Bio may reshape the future of pulmonary biologics Shilpa Medicare leads funding round in Alveolus Bio to accelerate Phase 2 COPD trials and first-in-human studies for novel inhaled therapeutics. byPallavi MadhirajuAugust 4, 2025